These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25938046)

  • 21. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
    Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
    Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
    Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
    Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
    BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short Term Presence of Subretinal Fluid in Central Serous Chorioretinopathy Affects Retinal Thickness and Function.
    Gawęcki M; Jaszczuk A; Grzybowski A
    J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33114519
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial.
    Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A
    Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
    Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
    Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anatomical and Functional Changes of the Retina and the Choroid after Resolved Chronic CSCR.
    Toto L; D'Aloisio R; Mastropasqua R; Di Antonio L; Di Nicola M; Di Martino G; Evangelista F; Erroi E; Doronzo E; Mariotti C
    J Clin Med; 2019 Apr; 8(4):. PubMed ID: 30959979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
    Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G;
    Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy.
    Daruich A; Matet A; Dirani A; Gallice M; Nicholson L; Sivaprasad S; Behar-Cohen F
    Transl Vis Sci Technol; 2016 Mar; 5(2):2. PubMed ID: 26966638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical Dexamethasone as an Adjuvant to Mineralocorticoid Receptor Antagonists for the Treatment of Recalcitrant Central Serous Chorioretinopathy.
    Wong A; Zhu D; Li AS; Lee JG; Ferrone PJ
    Ophthalmic Surg Lasers Imaging Retina; 2022 Dec; 53(12):659-665. PubMed ID: 36547963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report.
    Gruszka A
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1369-73. PubMed ID: 23740451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
    Lotery A; Sivaprasad S; O'Connell A; Harris RA; Culliford L; Ellis L; Cree A; Madhusudhan S; Behar-Cohen F; Chakravarthy U; Peto T; Rogers CA; Reeves BC;
    Lancet; 2020 Jan; 395(10220):294-303. PubMed ID: 31982075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral Eplerenone Versus Observation in the Management of Acute Central Serous Chorioretinopathy: A Prospective, Randomized Comparative Study.
    Venkatesh R; Pereira A; Jayadev C; Prabhu V; Aseem A; Jain K; Bavaharan B; Yadav NK; Chhablani J
    Pharmaceuticals (Basel); 2020 Jul; 13(8):. PubMed ID: 32751370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline Predictive Factors of Visual Outcome and Persistence of Subretinal Fluid Based on Morphologic Changes in Spectral Domain Optical Coherence Tomography in Patients with Idiopathic Central Serous Chorioretinopathy.
    Suwal B; Khadka D; Shrestha A; Shrestha S; Shrestha N; Khatri B
    Clin Ophthalmol; 2019; 13():2439-2444. PubMed ID: 31849441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA).
    Sulzbacher F; Schütze C; Burgmüller M; Vécsei-Marlovits PV; Weingessel B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1581-1590. PubMed ID: 31037488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy.
    Shulman S; Goldenberg D; Schwartz R; Habot-Wilner Z; Barak A; Ehrlich N; Loewenstein A; Goldstein M
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):15-22. PubMed ID: 25794988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eplerenone Versus Observation in the Treatment of Acute Central Serous Chorioretinopathy: A Retrospective Controlled Study.
    Zucchiatti I; Sacconi R; Parravano MC; Costanzo E; Querques L; Montorio D; Bandello F; Querques G
    Ophthalmol Ther; 2018 Jun; 7(1):109-118. PubMed ID: 29442283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy.
    Gergely R; Kovács I; Récsán Z; Sándor GL; Czakó C; Nagy ZZ; Ecsedy M
    Sci Rep; 2020 Oct; 10(1):16621. PubMed ID: 33024222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature.
    Chatziralli I; Vlachodimitropoulou A; Daoula C; Vrettou C; Galani E; Theodossiadis G; Theodossiadis P
    Int J Retina Vitreous; 2018; 4():33. PubMed ID: 30250750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.